Patient P-01713

Synthetic patientNBL-101 · Day 107 · 35–44 · F · baseline S04Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Favorable

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Stable

Discontinuation risk

49%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S04
Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 45 SC-12 recommended — Supportive Compound SC-12
Day 46 Patient accepted — Started SC-12 in the companion
Day 52 GI symptom burden −20% vs expected — Supportive Compound SC-12
Day 57 ME-01 recommended — Monitoring Escalation ME-01
Day 58 Tolerance state changed — Unstable → Improving
Day 58 Patient accepted — Started ME-01 in the companion
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 61 Patient accepted — Started GI-04 in the companion
Day 61 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 69 GI symptom burden −22% vs expected — GI Support Protocol GI-04
Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days

Toxicity-4
Inflammatory activity-3
Nutritional resilience-3
Treatment adherence+2

What helped?

Supportive Compound SC-12Day 45
Result: symptom burden −20%
Monitoring Escalation ME-01Day 57
Result: deterioration detected before clinical escalation
GI Support Protocol GI-04Day 60
Result: symptom burden −22%

LIFE OS recommendation

Dietary Support Protocol NP-02

54%

probability of meaningful tolerance improvement

284 similar trajectories
68% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

45.3/100

improving · -1.7 vs previous 14 d

Toxicity

Blood

35.8/100

improving · -3.4 vs previous 14 d

Sleep quality

Wearable

44.2/100

improving · +4.4 vs previous 14 d

Energy level

Daily log

3.2/10

improving · +0.2 vs previous 14 d

Stress level

Daily log

5.9/10

improving · -0.3 vs previous 14 d

Steps

Wearable

7,960

stable · +188 vs previous 14 d

Adherence

Companion

51.7 %

stable · +0.4 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 37 from the failing basin, 50 from restoration.

Good elements to keep

Supportive Compound SC-12
intervention · steering +34.4
GI Support Protocol GI-04
intervention · steering +32.3
Monitoring Escalation ME-01
intervention · steering +4.7

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
Low microbial diversity
hidden · steering -7.7
Bacteroides fragilis elevated
hidden · steering -7.4
IL6 high-expression variant
hidden · steering -7.3
Dietary fat load
detractor · GI +3.7 next day
Spicy / capsaicin
detractor · GI +3.1 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+3.7detractor · 95%
Spicy / capsaicin
+3.1detractor · 81%
Simple carbohydrates
+3detractor · 84%
Insoluble fibre
+1.2no signal · 30%
Alcohol
-0.4no signal · 15%
Histamine load
+0.3no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 41/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 48
Autonomic recovery ↑45
- WearableResting HR 75 bpm
- WearableShort sleep window
Mucosal barrier integrity ↓20
- Daily logGI symptom score 45 and rising

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.9 · butyrate capacity 41/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 59 ms
Sleep: 6.9 h
Steps: 8,092
Resting HR: 75 bpm

Daily log: GI score 45, nutritional resilience 44, adherence 52.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01377	26%	S11	AD-05	no change	42
P-01483	26%	S14	AD-05	no change	35
P-01541	25%	S09	AD-05	no change	43
P-01689	27%	S13	BR-03	no change	50
P-01371	31%	S06	CR-01	improved	63
P-01708	30%	S07	CR-01	improved	59
P-01696	28%	S20	CR-01	improved	59
P-01388	27%	S17	CR-01	improved	59
P-01442	27%	S13	CR-01	improved	61
P-01430	26%	S05	CR-01	improved	54
P-01835	26%	S17	CR-01	improved	56
P-01458	52%	S14	GI-04	improved	44